The impact of the TIM gene family on tumor immunity and immunosuppression

Pardoll D . Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003; 21: 807–839.

Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ . Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29: 235–271.

Mellman I, Coukos G, Dranoff G . Cancer immunotherapy comes of age. Nature 2011; 480: 480–489.

Rosenberg SA . Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 2012; 4: 127ps8.

Mantovani A, Allavena P, Sica A, Balkwill F . Cancer-related inflammation. Nature 2008; 9: 361–371.

Johansson M, Denardo DG, Coussens LM . Polarized immune responses differentially regulate cancer development. Immunol Rev 2008; 222: 145–154.

Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.

Grivennikov SI, Greten FR, Karin M . Immunity, inflammation, and cancer. Cell 2010; 140: 883–899.

Lin WW, Karin M . A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175–1183.

Schreiber RD, Old LJ, Smyth MJ . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565–1570.

Dunn GP, Old LJ, Schreiber RD . The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329–360.

Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S . Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181–273.

Groh V, Wu J, Yee C, Spies T . Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734–738.

Gabrilovich DI, Ostrand-Rosenberg S, Bronte V . Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253–268.

Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–264.

Postow MA, Harding J, Wolchok JD . Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J 2013; 18: 153–159.

Zou W . Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263–274.

Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9: 562–567.

Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203: 871–881.

Coussens LM, Zitvogel L, Palucka AK . Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013; 339: 286–291.

Luraishy A, Karin M, Grivennilov SI . Tumor promotion via injury- and death-induced inflammation. Immunity 2011; 35: 467–477.

Huang X, Bai X, Cao Y, Wu J, Huang M, Tang D et al. Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med 2010; 207: 505–520.

Kikushige Y, Shima T, Takayanagi S, Urata S, Miyamoto T, Iwasaki H et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010; 7: 708–717.

Kuchroo VK, Meyers JH, Umetsu DT, DeKruyff RH . TIM family of genes in immunity and tolerance. Adv Immunol 2006; 91: 227–249.

Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH . TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev 2010; 235: 172–189.

Jayaraman P, Sada-Ovalle I, Beladi S, Anderson AC, Dardalhon V, Hotta C et al. Tim3 binding to galectin-9 stimulates antimicrobial immunity. J Exp Med 2010; 207: 2343–2354.

Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012; 13: 832–842.

Mattei F, Schiavoni G . TIM-3 as a molecular switch for tumor escape from innate immunity. Front Immunol 2013; 9: 418.

Degauque N, Mariat C, Kenny J, Zhang D, Gao W, Vu MD et al. Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. J Clin Invest 2008; 118: 735–741.

de Souza AJ, Oriss TB, O'Malley KJ, Ray A, Kane LP . T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation. Proc Natl Acad Sci USA 2005; 102: 17113–17118.

Umetsu SE, Lee WL, McIntire JJ, Downey L, Sanjanwala B, Akbari O et al. TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. Nat Immunol 2005; 6: 447–454.

Encinas JA, Janssen EM, Weiner DB, Calarota SA, Nieto D, Moll T et al. Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma. J Allergy Clin Immunol 2005; 116: 1343–1449.

Xiao S, Zhu B, Jin H, Zhu C, Umetsu DT, DeKruyff RH et al. Tim-1 stimulation of dendritic cells regulates the balance between effector and regulatory T cells. Eur J Immunol 2011; 41: 1539–1549.

Kobayashi N, Karisola P, Peña-Cruz V, Dorfman DM, Jinushi M, Umetsu SE et al. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity 2007; 27: 927–840.

Balasubramanian S, Kota SK, Kuchroo VK, Humphreys BD, Strom TB . TIM family proteins promote the lysosomal degradation of the nuclear receptor NUR77. Sci Signal 2012; 5: ra90.

Hanna RN, Carlin LM, Hubbeling HG, Nackiewicz D, Green AM, Punt JA et al. The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C-monocytes. Nat Immunol 2011; 12: 778–785.

Hanna RN, Shaked I, Hubbeling HG, Punt JA, Wu R, Herrley E et al. NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis. Circ Res 2012; 110: 416–427.

Chakravarti S, Sabatos CA, Xiao S, Illes Z, Cha EK, Sobel RA et al. Tim-2 regulates T helper type 2 responses and autoimmunity. J Exp Med 2005; 202: 437–444.

Knickelbein JE, de Souza AJ, Tosti R, Narayan P, Kane LP . Cutting edge: inhibition of T cell activation by TIM-2. J Immunol 2006; 177: 4966–4970.

Kumanogoh A, Marukawa S, Suzuki K, Takegahara N, Watanabe C, Ch'ng E et al. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. Nature 2002; 419: 629–633.

Delgoffe GM, Woo SR, Turnis ME, Gravano DM, Guy C, Overacre AE et al. Stability and function of regulatory T cells is maintained by a neuropilin-1–semaphorin-4a axis. Nature 2013; 501: 252–256.

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942–949.

Erdman SE, Sohn JJ, Rao VP, Nambiar PR, Ge Z, Fox JG et al. CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res 2005; 65: 3998–4004.

de Visser KE, Korets LV, Coussens LM . De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005; 7: 411–243.

Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002; 415: 536–541.

Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6: 1245–1252.

Rangachari M, Zhu C, Sakuishi K, Xiao S, Karman J, Chen A et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nat Med 2012; 18: 1394–1400.

Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008; 205: 2763–2779.

Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson L, Livingston S, McMahon BJ et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol 2009; 83: 9122–9130.

Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2012; 56: 1342–1351.

Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011; 117: 4501–4510.

Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010; 207: 2175–2186.

Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS ONE 2012; 7: e30676.

Jinushi M, Yagita H, Yoshiyama H, Tahara H . Putting the brakes on anticancer therapies: suppression of innate immune pathways by tumor-associated myeloid cells. Trends Mol Med 2013; 19: 536–545.

Ndhlovu LC, Lopez-Vergès S, Barbour JD, Jones RB, Jha AR, Long BR et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 2012; 119: 3734–3743.

Joyce JA, Pollard JW . Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239–252.

Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S . Identification of Tim4 as a phosphatidylserine receptor. Nature 2007; 450: 435–439.

Wong K, Valdez PA, Tan C, Yeh S, Hongo J, Ouyang W . Phosphatidylserine receptor Tim-4 is essential for the maintenance of the homeostatic state of resident peritoneal macrophages. Proc Natl Acad Sci USA 2010; 107: 8712–8717.

Rodriguez-Manzanet R, Sanjuan MA, Wu HY, Quintana FJ, Xiao S, Anderson AC et al. T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proc Natl Acad Sci USA 2010; 107: 8706–8711.

Albacker LA, Karisola P, Chang YJ, Umetsu SE, Zhou M, Akbari O et al. TIM-4, a receptor for phosphatidylserine, controls adaptive immunity by regulating the removal of antigen-specific T cells. J Immunol 2010; 185: 6839–6849.

Jinushi M, Sato M, Kanamoto A, Itoh A, Nagai S, Koyasu S et al. Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms. J Exp Med 2009; 206: 1317–1326.

Lemke G, Rothlin CV . Immunobiology of the TAM receptors. Nat Rev Immunol 2008; 8: 327–336.

Baghdadi M, Nagao H, Yoshiyama H, Akiba H, Yagita H, Dosaka-Akita H et al. Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. Cancer Immunol Immunother 2013; 62: 629–637.

Gregory CD, Pound JD . Cell death in the neighborhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues. J Pathol 2011; 223: 177–194.

Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC . Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207: 2187–2194.

Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ . Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011; 71: 3540–3551.

Sun HW, Wu C, Tan HY, Wang QS . A new development of FG–CC′ siRNA blocking interaction of Tm-1 and Tim-4 can enhance DC vaccine against gastric cancer. Hepatogastroenterology 2012; 59: 2677–2682.

DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T . Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012; 482: 405–409.

DuPage M, Cheung AF, Mazumdar C, Winslow MM, Bronson R, Schmidt LM et al. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 2011; 19: 72–85.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–723.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–2454.